secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0000318154-26-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen EVP and CTO David M. Reese to retire June 30, 2026; roles redistributed
-----------------------------------------------------------------------------

- David M. Reese retires as EVP and CTO effective June 30, 2026; responsibilities split among Bradner, Gordon, Griffith starting June 1.
- James Bradner becomes EVP of R&D, AI and Data; Sean Bruich named SVP and CTO.
- Murdo Gordon takes EVP of Amgen Global Markets and Policy; Paul Burton remains Chief Medical Officer.
- Reese joined Amgen in 2005, led R&D from 2018-2023, and served as inaugural CTO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815426000048/0000318154-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815426000048/amgn-20260422.htm
  HTML page:      https://secwatch.observer/filing/0000318154-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer